- Gus Cairns | 06 April 2012
Twice as many HIV-positive gay men are now being infected with hepatitis C as HIV-positive injecting drug users, a Swiss study presented to the 19th Retrovirus Conference has found.New hepatitis ...
- Gus Cairns | 19 March 2012
A meta-analysis of HIV-negative
gay men’s sexual behaviour and HIV incidence rate in four HIV prevention studies,
presented earlier this month at the 19th Conference on Retroviruses and
Opportunistic Infections (CROI), has found ...
- Gus Cairns | 18 March 2012
A longitudinal
study from KwaZulu Natal province in South Africa is the first study from the
global south to relate an increase in the proportion of adults on HIV treatment
to a fall ...
- Theo Smart | 15 March 2012
Giving a six- to nine-month course of isoniazid preventive
therapy (IPT) at a ‘community-wide level’
– to everyone working at randomly
selected South African gold mines
– had no
effect on TB incidence, ...
- Liz Highleyman | 14 March 2012
People with detectable HIV viral load and advanced immune
deficiency are likely to experience greater decreases in lung function over
time, with high viral load linked to more impairment than smoking, according ...
- Liz Highleyman | 14 March 2012
Cholesterol-lowering statin drugs showed a trend toward
lowering the risk of non-AIDS events and death among people with HIV in a large
US cohort, researchers
reported last week at the 19th Conference on ...
- Liz Highleyman | 14 March 2012
The diabetes drug metformin can help stall progression
of calcium buildup in the coronary arteries of HIV-positive people with
metabolic abnormalities, potentially reducing their risk of cardiovascular
events, researchers reported last week at ...
- Liz Highleyman | 14 March 2012
Drug-drug interactions between direct-acting antiviral
agents for hepatitis C and some antiretroviral medications used to treat HIV
are common, but are often modest and can be managed with dose adjustments when
treating people ...
- Theo Smart | 13 March 2012
Current early infant diagnosis (EID)
protocols may need to be revised in the light of current WHO guidelines on the
prevention and treatment of HIV-infection in low-resourced settings, according
to Dr. Gayle Sherman ...
- Liz Highleyman | 13 March 2012
The Quad single-tablet regimen, an all-in-one pill
containing the experimental integrase inhibitor elvitegravir plus two other
antiretroviral drugs and a novel boosting agent, was as effective as the widely
used Atripla combination but ...
- Carole Leach-Lemens | 13 March 2012
The
incidence of Kaposi’s Sarcoma (KS) among HIV-infected adults on ART in Uganda
and Kenya remains high (346 per 100,000 person-years) until the CD4 cell count
rises above 350 cells/mm3, highlighting the importance ...
- Carole Leach-Lemens | 13 March 2012
Protease inhibitor-based treatment did not result in superior rates of viorologic suppression after two years when compared to NNRTI-based treatment when tested in a randomised study in the Democratic Republic ...
- Gus Cairns | 12 March 2012
A number of papers at the 19th
Conference on Retroviruses and Opportunistic Infections presented advances in research on HIV-related brain impairment
and neurocognitive problems.
A couple of problems have dogged
research into HIV-related brain ...
- Keith Alcorn | 12 March 2012
A very low CD4 count in the past, and a history of smoking,
are the most consistent risk factors to emerge from large studies of risks for
developing both AIDS-defining and non-AIDS-defining ...
- Gus Cairns | 10 March 2012
The 19th
Conference on Retroviruses and Opportunistic Infections (CROI) heard this week that
a tenfold increase in medical male circumcision (MMC) in non-Muslim men in the
Rakai district of Uganda has led to ...
- Gus Cairns | 10 March 2012
Two studies of people with HIV
in Rakai, Uganda and Mombasa, Kenya presented at the 19th Conference on
Retroviruses and Opportunistic Infections show that the rate at which they
acquired second, subsequent strains ...
- Liz Highleyman | 09 March 2012
The next generation integrase inhibitor dolutegravir maintains viral
suppression and remains safe after two years of use, according to a small study
presented Wednesday at the 19th
Conference on Retroviruses and Opportunistic Infections ...
- Theo Smart | 09 March 2012
Two studies generated conflicting data and rather mixed
messages about whether it is safe or advisable to strategically interrupt
treatment in children (STIC) who have initiated antiretroviral therapy (ART)
during infancy
– in ...
- Liz Highleyman | 08 March 2012
GS-7340, a pro-drug of tenofovir that reaches higher concentrations in
cells, had superior efficacy and may be more suitable for inclusion in
co-formulations, researchers reported on 7 March at the 19th Conference ...
- Keith Alcorn | 08 March 2012
Routine viral load testing did not catch failure of
first-line treatment earlier than discretionary viral load testing, but it did
reduce the period on failing treatment by nearly a year in a ...
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...